37 results about "HUMAN THYMUS" patented technology

The invention provides an anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody and an application thereof. The anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody comprises three heavy chain complementary determining regions (CDR-H1, CDR-H2 and CDR-H3) and three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3), and (a) the amino acid sequence of the CDR-H1 is as shown in SEQ ID NO: 1, and (b) the amino acid sequence of CDR-H2 is as shown in SEQ ID NO: 2; (c) the amino acid sequence of the CDR-H3 is as shown in SEQ ID NO: 3; (d) the amino acid sequence of the CDR-L1 is as shown in SEQ ID NO: 4; (e) the amino acid sequence of the CDR-L2 is as shown in SEQ ID NO: 5; and the amino acid sequence of the (f) CDR-L3 is as shown in SEQ ID NO: 6. Compared with an anti-human TSLP monoclonal antibody Tezepelumab (prepared according to sequence expression disclosed in the patent), the anti-human TSLP monoclonal antibody has the advantages that the affinity of the anti-human TSLP monoclonal antibody combined with the human TSLP is equivalent, the neutralizing activity of the anti-human TSLP monoclonal antibody at the cellular level is superior to that of the Tezepelumab, and the anti-human TSLP monoclonal antibody is expected to show a good clinical effect in the aspect of preventing and treating related diseases.

The present invention belongs to the field of pharmacy and cell biology, and relates to an efficient and reliable high content CCR4 antagonist screening cell model using human chemokine receptor 4 as a target, and a screening method thereof. According to the present invention, a cell line being subjected to human CCR4-enhanced green fluorescent protein fusion expression introducing is established, excitation is performed through human thymus activation regulated chemokine and human macrophage chemotatic factor, the CCR4 with green fluorescent protein is induced to produce re-distribution so as to form green fluorescent particles, and the CCR4 antagonist screening cell model for high-content screening is established; the bioactivity of the compound is evaluated by determining the CCR4 green fluorescent particle formation excited or inhibited by the screened compound through the model; and the established drug screening model is the sensitive, efficient and reliable CCR4 antagonist screening cell model suitable for high-throughput and high-content screening, and the method is the sensitive, efficient and reliable method suitable for high-throughput and high-content screening.

The present invention is gene engineering bacteria with high efficiency expression of human alpha 1-thmulin and its construction and application, and belongs to the field of bioengineering technology. The gene engineering bacteria is colibacillus DH5-alpha, BL21(DE3) or BLR(DE3), and carry plasmid containing 1-16 alpha 1-thmulin genes. The plasmid promoter is IPTG induced promoter Lac, Tac of PT7, such as plasmid pET series, pGEX series, pQE series, etc. On DNA level, DNA sequences containing alpha 1-thmulin gene are connected serially to form serial body and constitute one series of expression vectors, which transform colibaccilus to obtain one series of gene engineering bacteria with high efficiency expression of human alpha 1-thmulin. The gene engineering bacteria may be used in preparing human alpha 1-thmulin samples. The present invention has high yield and low cost of human alpha 1-thmulin samples.

The present invention relates to a peptide comprising a specific amino acid sequence possessing human thymosin β-4 (Tβ4) activities and its uses. The peptide of this invention has identical or similar functions or actions to human Tβ4 and its biological activity is almost identical to natural-occurring Tβ4. In addition, the peptide of this invention exhibits much higher stability and skin permeation than natural-occurring Tβ4. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on improvement in thymosin β-4-effective disorders or conditions. In addition, the peptide of this invention can be advantageously applied to drugs, cosmetics, toothpaste and compositions for mouth cleaning and caring, most preferably, cosmetics. Specifically, the peptide of this invention is advantageously applied to cosmetics for promoting hair growth.

The present disclosure relates to making a hybrid pig-human thymic tissue and using the hybrid thymic tissue to induce tolerance in xenotransplantation. The hybrid thymic tissue can also be used for restoring or inducing immunocompetence in a recipient as well as restoring or promoting the thymus-dependent ability for T cell progenitors to develop into mature functional T cells in a recipient.

The present invention belongs to the field of pharmacy and cell biology, and relates to an efficient and reliable high content CCR4 antagonist screening cell model using human chemokine receptor 4 as a target, and a screening method thereof. According to the present invention, a cell line being subjected to human CCR4-enhanced green fluorescent protein fusion expression introducing is established, excitation is performed through human thymus activation regulated chemokine and human macrophage chemotatic factor, the CCR4 with green fluorescent protein is induced to produce re-distribution so as to form green fluorescent particles, and the CCR4 antagonist screening cell model for high-content screening is established; the bioactivity of the compound is evaluated by determining the CCR4 green fluorescent particle formation excited or inhibited by the screened compound through the model; and the established drug screening model is the sensitive, efficient and reliable CCR4 antagonist screening cell model suitable for high-throughput and high-content screening, and the method is the sensitive, efficient and reliable method suitable for high-throughput and high-content screening.

The invention discloses a combined chemotherapeutic agent for transplantation pretreatment of thalassemia stem cells in children, which comprises the following components: 5 mg / m<2>*5 days of cladrobin, 1.8 g / m<2>*2 days of cyclophosphamide, 4-4.8 mg / kg*3 days of busulfan and 2.5 mg / kg*2 days of anti-human thymus globulin. The combined chemotherapeutic agent is based on the cladrobin, and the cladrobin is combined with the cyclophosphamide, the busulfan and anti-human thymus globulin to perform pre-treatment large-dose chemotherapy before transplantation of Mediterranean stem cells of children, so that the compliance and tolerance of the chemotherapy are improved, the immunosuppression strength is increased, the transplantation success rate of transplantation of stem cells of a patient isimproved, the transplantation-related complications are reduced, the transplantation curative effect is improved, the survival time of the patient is prolonged, and the combined chemotherapeutic agenthas good social benefit and economic benefit and wide clinical application prospect. The efficient and safe pretreatment scheme can be used for transplantation of thalassemia stem cells in children,and the transplantation survival rate is improved.

This application provides an anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody and its application. The anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody of the present application comprises three heavy chain complementarity determining regions (CDR‑H1, CDR‑H2 and CDR‑H3) and three light chain complementarity determining regions (CDR‑L1 , CDR‑L2 and CDR‑L3), wherein, (a) the amino acid sequence of CDR‑H1 is shown in SEQ ID NO: 1; (b) the amino acid sequence of CDR‑H2 is shown in SEQ ID NO: 2; (c ) The amino acid sequence of CDR‑H3 is shown in SEQ ID NO: 3; (d) the amino acid sequence of CDR‑L1 is shown in SEQ ID NO: 4; (e) the amino acid sequence of CDR‑L2 is shown in SEQ ID NO: 5 and (f) the amino acid sequence of CDR-L3 is shown in SEQ ID NO:6. The anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody, compared with the anti-human TSLP monoclonal antibody Tezepelumab (expressed and prepared according to the sequence disclosed in the patent), has comparable affinity for binding human TSLP, and is in the cell level. It is more active than Tezepelumab and is expected to show good clinical effects in the prevention and treatment of related diseases.

The invention provides a humanized mouse tumor model, which is characterized in that the humanized mouse tumor model is obtained by transplanting human thymus tissue and CD34+ hematopoietic stem cells homologous to the thymus tissue. The present invention constructs a humanized mouse tumor model transplanted from thymus and hematopoietic stem cells for the first time. The humanized mouse tumor model has confirmed that it has a complete immunosuppressive microenvironment, and is suitable for the overall evaluation of solid tumor immunotherapy, and can be used to evaluate the feasibility and effectiveness of immunotherapy. The invention makes up for the singleness and incompleteness of the existing tumor immunotherapy evaluation methods, provides reference value for clinical research, and complements the key role of the human immune system in immunotherapy compared with traditional models.

The invention discloses a method for establishing a PDX (Patient Derived Xenograft) model of human blood tumor. The method comprises the steps of extracting a blood tumor cell of a patient, adding rabbit anti-human thymocyte immunoglobulin ATG (Anti-Thymocyte Globulin) and patient autologous serum, mixing, incubating and after completing the incubation, re-suspending the obtained cell and inoculating in a mouse; and feeding the inoculated mouse with CsA (Cyclosporine A) and lasting for 5-10 days starting from 2 days before the inoculation of the blood tumor cell. The method disclosed by the invention has the beneficial effects that a novel highly immunodeficient NCG mouse independently developed in China is firstly adopted to establish a human leukemia PDX model; by orally taking human thymocyte immunoglobulin pretreatment sample combined with the cyclosporine for a long term, donor-derived T cells are removed and inhibited; and by combining the toxic effect of the ATG on lymphocytes with the functional blocking effect of the CsA on T lymphocytes, the immune function of the T lymphocytes can be persistently inhibited and the success rate of PDX modeling of the blood tumor is significantly improved.

A recombinant plasmid with human extrasin beta4-gene carrier is prepared by inserting human extrasin beta4-gene into eukaryote expression starter to construct recombinant plasmid, entering it into striped muscle cell, synthesizing T beta-4 by cell protein synthetic system and secreting to extracellular region. It can improve wound healed, prevent cell from death and be used to repair skin and heart damages.

The invention discloses a method to manufacture biology polypeptide, especially a method to make natural human thymosin by gene series express method. It contains compounding two polynucleotide section, compounding double enzyme cut, T alpha 1 gene three times connecting in series, constructing high efficiency expression, constructing engineering fungus, expressing T alpha 1 polypeptide six series bodies in engineering fungus, purifying and cracking. The invention could abundantly express aim albumen, and it has simple technology, easy to operate and low cost.

The present invention relates to human thymosin β4 triploid protein, encoding genes and methods for isolating and purifying the same. The amino acid sequence of the human thymosin β4 triploid protein involved is shown in SED ID NO: 1; the coding gene sequence involved is shown in SED ID NO: 2; the separation and purification method involved is to use an affinity chromatography column Carry out separation and purification. The recombinant human thymosin β4 tandem triploid of the present invention can significantly improve the immune response performance of T-lymphocytes as detected by the rosette experiment; the mouse fur growth experiment shows that the recombinant human thymosin β4 tandem triploid can significantly promote hair removal agent treatment in mice Growth in the fur.

The invention relates to the technical field of antibodies, in particular to a human thymus stromal lymphopoietin monoclonal antibody and an application thereof. The TSLP antibody provided by the present invention can specifically bind hTSLP with high affinity, and can effectively inhibit the binding of TSLP to its receptor, thereby inhibiting TSLP from activating downstream signaling pathways and activating immune cells. The TSLP antibody provided by the present invention is used for the content detection of hTSLP and allergic asthma, chronic obstructive pulmonary disease, allergic dermatitis, allergic rhinitis, allergic sinusitis, eosinophilic esophagitis, allergic conjunctivitis, inflammatory bowel disease It is of great significance in the diagnosis, treatment and prognosis of inflammatory or allergic inflammatory diseases such as atopic dermatitis or atopic dermatitis.

The application discloses a method for preparing a concentrated solution of anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody, comprising the following steps: Concentrate the solution to obtain the first concentrated sample; Step 2: Replace the first concentrated sample with a buffer solution to obtain a replacement concentrated solution; Step 3: Mix the replaced concentrated solution and the mother liquor of the amino acid protective agent to obtain a mixed solution, and the The above mixed solution was concentrated by ultrafiltration to obtain a second concentrated sample. The preparation method described in this application can reduce the viscosity of high-concentration antibody drug solution and improve the stability. The method is simple and easy, and can be scaled up for production, which can ensure the high purity of the sample and obtain a high recovery rate.

This application discloses a liquid preparation of anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody, comprising anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody and amino acid protective agent, anti-human thymus stromal lymphocytes The protein concentration of the TSLP monoclonal antibody is 100-300mg / ml, and the amino acid concentration of the amino acid protection agent is 10-500mM. The monoclonal antibody comprises three heavy chain complementarity determining regions (CDR‑H1, CDR‑H2 and CDR‑H3) and three light chain complementarity determining regions (CDR‑L1, CDR‑L2 and CDR‑L3), wherein: The amino acid sequence of CDR‑H1 is shown in SEQ ID NO: 1; the amino acid sequence of CDR‑H2 is shown in SEQ ID NO: 2; the amino acid sequence of CDR‑H3 is shown in SEQ ID NO: 3; the amino acid of CDR‑L1 The sequence is shown in SEQ ID NO: 4; the amino acid sequence of CDR‑L2 is shown in SEQ ID NO: 5; the amino acid sequence of CDR‑L3 is shown in SEQ ID NO: 6. The liquid formulation of the present application has a low viscosity and can be easily injected with a syringe, so it can be used as an injection, especially a subcutaneous injection.

The invention relates to a kit used for diagnosing the acute exacerbation period of chronic obstructive pulmonary disease. The kit comprises a cell factor and an enzyme labeled antibody thereof and is characterized in that the cell factor is interleukin 9, interleukin 18 binding protein A, C-C sequence ligand 28, a human skin T cell capture chemokine, a Beta cytokine, a monocyte chemoattractant protein-3, a monocyte chemoattractant protein-4, a lymphotoxin induced protein entering the T cell, a macrophage-derived chemokine, a human bone marrow suppression factor 1, a human macrophage stimulating protein, an osteopontin and a human thymus expressed chemokine. The invention firstly proposes that the cell factor can be used as a leading indicator for diagnosis of the acute exacerbation period of the chronic obstructive pulmonary disease.